New trial
Phase 1 Trial of QTX3544 in KRAS G12V Advanced Solid Tumors
- Trial ID
- NCT06715124 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Location
- 4 Locations
- Published in
- New in Oncology - May 14, 2025
Quanta Therapeutics is evaluating QTX3544—a KRAS inhibitor—both as monotherapy and in combination with cetuximab in patients with advanced solid tumors harboring KRAS G12V mutations through dose escalation and expansion phases to assess safety, tolerability, and preliminary antitumor activity.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings